ENBIOTIX

The mission of Spexis is to discover and develop innovative medicines to help patients who are in need for novel transformative treatments... Spexis AG is a combination of the two legacy companies, Polyphor, a publicly listed Swiss biotech and EnBiotix, a privately held US biotech. In December 2021, two companies - Polyphor and EnBiotix - teamed up to join forces and formed Spexis. Effective upon the merger, Polyphor acquired all of the outstanding capital stock of EnBiotix in exchange for shares of Polyphor common stock, and is traded under a new ticker symbol (Ticker.SW) and new company name Spexis on the SIX Swiss Exchange... Headquartered in Switzerland and Boston, two global biotech-hubs, our ambition is to develop Spexis into a leading biopharmaceutical company with a strategic focus on rare diseases, oncology and antimicrobial resistance. With a strong scientific core, our drug discovery and research efforts are led by our in house scientist via leveraging our discovery..

Also known as: EnBiotix Inc., Spexis, Spexis Ltd.

Primary location: Allschwil Switzerland